<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="63725"><DrugName>flubrobenguane F18</DrugName><DrugNamesKey><Name id="43148318">flubrobenguane F18</Name></DrugNamesKey><DrugSynonyms><Name><Value>fluorine-18-based PET imaging agent (intravenous, heart failure), Lantheus</Value></Name><Name><Value>18F-based PET imaging agent (intravenous, heart failure), Lantheus</Value></Name><Name><Value>18F-LMI-1195</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>flubrobenguane F18</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Fluorine-18-flubrobenguane</Value></Name><Name><Value>18F-flubrobenguane</Value></Name><Name><Value>LMI-1195</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1037359-47-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004416">Lantheus Medical Imaging Inc</CompanyOriginator><CompaniesPrimary><Company id="1004416">Lantheus Medical Imaging Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="63725" type="Drug"><TargetEntity id="707693" type="siDrug">Flubrobenguane F18</TargetEntity></SourceEntity><SourceEntity id="1004416" type="Company"><TargetEntity id="4297094323" type="organizationId">Lantheus Medical Imaging Inc</TargetEntity></SourceEntity><SourceEntity id="1128" type="ciIndication"><TargetEntity id="C7A" type="ICD10"></TargetEntity><TargetEntity id="209" type="ICD9"></TargetEntity><TargetEntity id="10052399" type="MEDDRA"></TargetEntity><TargetEntity id="D018358" type="MeSH"></TargetEntity><TargetEntity id="-1333045072" type="omicsDisease"></TargetEntity><TargetEntity id="1422" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1128">Neuroendocrine tumor</Indication><Indication id="55">Cardiac failure</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="13176">Noradrenaline transporter modulator</Action></ActionsPrimary><ActionsSecondary><Action id="5720">Radiodiagnostic</Action><Action id="5555">PET contrast agent</Action><Action id="7220">Neoplasm diagnostic agent</Action><Action id="7210">Cardiovascular diagnostic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="731">Imaging</Technology><Technology id="724">Radiolabeling</Technology></Technologies><EphmraCodes><Ephmra><Code>T1G</Code><Name>RADIODIAGNOSTIC AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-26T15:51:17.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>2009-06-18T12:04:29.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1004416" linkType="Company"&gt;Lantheus Medical Imaging&lt;/ulink&gt; is developing  flubrobenguane F18 (LMI-1195; 18F-LMI-1195),  a small-molecule   iv  PET imaging agent  that targets the norepinephrine transporter (NET), for the potential assessment of cardiac neuronal function in patients with heart failure and the potential diagnosis of neuroendocrine tumors,   including pheochromocytomas and paragangliomas [&lt;ulink linkID="1019073" linkType="Reference"&gt;1019073&lt;/ulink&gt;], [&lt;ulink linkID="1103989" linkType="Reference"&gt;1103989&lt;/ulink&gt;], [&lt;ulink linkID="1106358" linkType="Reference"&gt;1106358&lt;/ulink&gt;], [&lt;ulink linkID="1972409" linkType="Reference"&gt;1972409&lt;/ulink&gt;], [&lt;ulink linkID="2168193" linkType="Reference"&gt;2168193&lt;/ulink&gt;]. In September 2009, a phase I trial began in the US [&lt;ulink linkID="1042726" linkType="Reference"&gt;1042726&lt;/ulink&gt;].By May 2010, a phase II study in patients with heart failure had been  terminated due to the company re-evaluating their clinical development path [&lt;ulink linkID="1111208" linkType="Reference"&gt;1111208&lt;/ulink&gt;].  In March 2012, the program was listed as being in phase I development [&lt;ulink linkID="1272283" linkType="Reference"&gt;1272283&lt;/ulink&gt;]. In October 2017, clinical data for patients suspected to have a pheochromocytoma or a paraganglioma were presented [&lt;ulink linkID="1972409" linkType="Reference"&gt;1972409&lt;/ulink&gt;]. By June 2019, a registrational phase III trial in patients with ischemic heart failure scheduled to undergo implantable cardioverter defibrillator (ICD) implantation was planned [&lt;ulink linkID="2168193" linkType="Reference"&gt;2168193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2019, the FDA granted flubrobenguane F18 Orphan designation for use as a diagnostic for the management of neuroendocrine tumors [&lt;ulink linkID="2168101" linkType="Reference"&gt;2168101&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Neuroendocrine tumors&lt;/subtitle&gt;In  June 2019, ongoing academic collaborations evaluating potential use of flubrobenguane F18 for the diagnosis and follow-up treatment of neuroendocrine tumors, such as pheochromocytomas and paragangliomas, had produced initial proof of concept data, and further clinical development was planned [&lt;ulink linkID="2168193" linkType="Reference"&gt;2168193&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, clinical data in patients (n = 16) with the suspicion of a pheochromocytoma or a paraganglioma were presented at the 30th EANM Congress in Vienna, Austria. There were no reports of adverse events observed after application of flubrobenguane F18. The most intense tracer accumulation was observed (mean standardized uptake values of organs in descending order of intensity): thyroid, salivary glands, pancreas, kidney, bladder, stomach, heart, adrenals liver, small bowels, spleen and lungs. When compared with I-123 MIBG scintigraphy, flubrobenguane F18 PET scan had the advantage of a substantially shorter (and single) scan, with an improved quality and comparable radiation dose [&lt;ulink linkID="1972409" linkType="Reference"&gt;1972409&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Heart failure&lt;/subtitle&gt;By June 2019, the company planned to conduct a registrational phase III trial in patients with ischemic heart failure scheduled to undergo implantable cardioverter defibrillator (ICD) implantation and at risk of sudden cardiac death, was planned. The trial would be designed to demonstrate that flubrobenguane F18 improves the risk stratification of these patients [&lt;ulink linkID="2168193" linkType="Reference"&gt;2168193&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, clinical data from a study evaluating the regional myocardial  uptake of flubrobenguane F18 in heart-healthy subjects (n = 17) were presented at the 65th SNMMI Annual Meeting in Philadelphia, PA. After flubrobenguane F18  PET/CT scans in patients without known coronary artery disease or cardiomyopathy, total left ventricular uptake observed was 7.1 (SUV mean) and 9.3 (SUV max), respectively. Tracer uptake of flubrobenguane F18 was highest in the septum (84%) and the lateral wall (81%), followed by the anterior (80%) and the inferior wall (73%) [&lt;ulink linkID="2048195" linkType="Reference"&gt;2048195&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, a State University of New York at Buffalo-sponsored observational cohort study (&lt;ulink linkID="335791" linkType="Protocol"&gt;NCT03493516&lt;/ulink&gt;; HL-130266; PAREPET II) was initiated in patients (n = 302) with ischemic cardiomyopathy in the US, to quantify sympathetic denervation using flubrobenguane F18 by PET scan. At that time, the trial was expected to get completed in December 2023 [&lt;ulink linkID="2038726" linkType="Reference"&gt;2038726&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, positive data from a phase II study were presented at the American College of Cardiology's 67th Annual Scientific Session. Data demonstrated that  PET imaging with flubrobenguane F18 provided a comparable measure of cardiac sympathetic nerve function and more favorable kinetics for early cardiac imaging than PET imaging with carbon-11 (C11) hydroxyephedrine (HED), the 9 patients  enrolled  in the study (n=2 healthy controls; n=6 ischemic cardiomyopathy patients with left ventricular (LV) ejection fraction (EF) =34Â±4; and n=1 non-ischemic cardiomyopathy patient with EF=37%)  underwent two separate PET imaging visits within one week, study findings suggest that flubrobenguane F18 yields a comparable estimate of cardiac sympathetic innervation as C11 HED. Flubrobenguane F18 retention index (r = 0.89, p&amp;lt;0.0001) and defect score (r = 0.99, p&amp;lt;0.0001) correlated highly with HED. LV-to-lung ratios were comparable between the two tracers. In addition, flubrobenguane F18 seems to offer more favorable kinetics for early cardiac imaging than HED, a significant difference in blood clearance was observed between the two tracers resulting in a LV-to-blood ratio of flubrobenguane F18 higher than HED within the first five minutes following administration (p&amp;lt;0.05) [&lt;ulink linkID="2012583" linkType="Reference"&gt;2012583&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a non-randomized, open-label, phase II study (&lt;ulink linkID="64806" linkType="Protocol"&gt;NCT01085175&lt;/ulink&gt;; LMI 1195-201) in patients with heart failure (n = 72) in the US was terminated, due to a re-evaluation of Lantheus' clinical development path. The study was designed to assess the safety and efficacy of flubrobenguane F18   [&lt;ulink linkID="1111208" linkType="Reference"&gt;1111208&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, an open-label, uncontrolled, single-group-assignment, biodistribution, phase I study (&lt;ulink linkID="57986" linkType="Protocol"&gt;NCT00891241&lt;/ulink&gt;; LMI 1195 -101) was planned in healthy volunteers (expected n = 12) in the US. Volunteers would receive a single 2 to 4 ml iv bolus injection of the drug. The primary endpoint was safety, and the secondary endpoint was dosimetry. The trial was expected to begin in July 2009 and be completed by December 2009 [&lt;ulink linkID="1019073" linkType="Reference"&gt;1019073&lt;/ulink&gt;]. In September 2009, the  non-randomized, single-dose  study was initiated. The study would also assess tolerability,  pharmacokinetics, metabolic data, PET imaging parameters and image quality [&lt;ulink linkID="1042726" linkType="Reference"&gt;1042726&lt;/ulink&gt;]. In June 2010, results were presented at the 57th SNM meeting in Salt Lake City, UT. Uptake to the myocardium suggested that clear images could be obtained with an acceptable radiation dose [&lt;ulink linkID="1104287" linkType="Reference"&gt;1104287&lt;/ulink&gt;].    In June 2018, further data were presented at the 65th SNMMI Annual Meeting in Philadelphia, PA. After application of flubrobenguane F18, short adverse events were not reported. Tracer accumulation (SUVmean) was higher in the thyroid (23), bladder (12), pancreas (13), kidneys (11), stomach (10), salivary glands (8) and left ventricle (7). Healthy adrenal gland tissue showed mean SUVmax and SUVmean of 13 and 8, respectively [&lt;ulink linkID="2048247" linkType="Reference"&gt;2048247&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2017, in vitro tracker update studies were presented at the 2017 SNMMI Annual Meeting in Denver, CO. Washout of flubrobenguane F18 from PC12 (rat pheochromocytoma) cells was enhanced by reserpine, while tracer uptake remained stable in the SK-N-SH (human neuroblastoma) cells that lack catecholamine storage vesicles. In PC12 cells, flubrobenguane F18 washout rate after 30 min of reserpine treatment was 53% and control buffer was 20.8% [&lt;ulink linkID="1936803" linkType="Reference"&gt;1936803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 2016 SNMMI Annual Meeting in San Diego, CA. Rabbits (n = 4) were injected with flubrobenguane F18 (25 Mbq, iv) followed by 201 TI (0.5 MBq), and 201TI was co-injected for dual-tracer analysis. In subepicardial portion, 201 TI uptake was significantly lower than in the subendocardial portion. Uptake of 201TI in subendocardial, mid-portion, and subepicardial portions was 90, 96, and 80% LV; and uptake of flubrobenguane F18 was 90, 96, and 84% LV, respectively [&lt;ulink linkID="1776522" linkType="Reference"&gt;1776522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, preclinical data were presented at the 2015 SNMMI Annual Meeting in Baltimore, MD. Both 11C-HED and flubrobenguane F18 showed stable cardiac tracer retention by in-vivo PET imaging. Desipramine added after tracer delivery increased only 11C-HED washout from the heart, whereas flubrobenguane F18 washout did not change [&lt;ulink linkID="1666772" linkType="Reference"&gt;1666772&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, preclinical data on the use of the agent for cancer diagnostics were presented at the 2013 EANM Congress in Lyon, France. Flubrobenguane F18 showed high and specific accumulation in pheochromocytomas in a preclinical in vivo MENX tumor model [&lt;ulink linkID="1488193" linkType="Reference"&gt;1488193&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, preclinical data were presented at the 60th Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging in Vancouver, Canada. In the isolated rabbit hearts, flubrobenguane F18 first pass extraction fraction was found to be 28.4 with a flow of 40 ml/min.  A minimal tracer washout was observed with a rate of 0.71%/min for the first 20 min and the wash out rate was not changed with the addition of desipramine, but was found to be increased by electrical stimulation [&lt;ulink linkID="1433542" linkType="Reference"&gt;1433542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, preclinical data were presented at the 59th SNM in Miami Beach, FL from a study evaluating defect area time-course changes in a rabbit model of myocardial infarction (MI) using flubrobenguane F18 and &lt;ulink linkID="54433" linkType="Drug"&gt;flurpiridaz F 18&lt;/ulink&gt;. The PET agents were capable of assessing cardiac denervation and perfusion defect area mismatch. Mismatch was best evaluated at early time point following MI. With time, the enlarged denervated area was reduced to a size similar to the perfusion defect area as a result of reinnervation [&lt;ulink linkID="1300017" linkType="Reference"&gt;1300017&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, preclinical data were presented at the 58th SNM meeting in San Antonio, TX. Tissue biodistribution studies in rats, rabbits and non-human primates demonstrated blockade of norepinephrine uptake 1  reduced heart uptake of flubrobenguane F18 by 82% in rabbits and 66% in non-human primates indicating neuronal uptake 1 to be the dominant transporter for the agent. There were no changes in heart uptake in rats following blockade [&lt;ulink linkID="1194244" linkType="Reference"&gt;1194244&lt;/ulink&gt;]. In further data presented at the meeting, the agent was demonstrated to be useful for evaluation of regional cardiac sympathetic denervation (RCSD) and re-innervation  and RCSD was found to increase the susceptibility of drug-induced QTc prolongation and arrhythmia [&lt;ulink linkID="1194246" linkType="Reference"&gt;1194246&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, preclinical data were presented for flubrobenguane F18 at the 57th SNM meeting in Salt Lake City, UT. The affinity of the compound for NET was found to be similar to that of norepinephrine. Scanning in rodents up to 1 h after injection gave clear PET images with low background activity  [&lt;ulink linkID="1103989" linkType="Reference"&gt;1103989&lt;/ulink&gt;], [&lt;ulink linkID="1106358" linkType="Reference"&gt;1106358&lt;/ulink&gt;]. Further data were presented on dosimetry in cynomolgus monkeys. In most organs, activity declined rapidly over the first hour followed by a much slower decline. Maximal dose to be administered to humans based on analysis of the results was calculated to be 454 MBq  [&lt;ulink linkID="1104290" linkType="Reference"&gt;1104290&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In November 2009, in vivo data were presented at the AHA Scientific Sessions in Orlando, FL. In the Dahl salt-sensitive rat heart failure model, heart uptake of flubrobenguane F18 reduced after the progression of heart failure from early to late-stage disease. PET imaging showed clear images with no interference in control rats [&lt;ulink linkID="1054775" linkType="Reference"&gt;1054775&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004416">Lantheus Medical Imaging Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-17T00:00:00.000Z</StatusDate><Source id="1042726" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1004416">Lantheus Medical Imaging Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-22T00:00:00.000Z</StatusDate><Source id="1972409" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004416">Lantheus Medical Imaging Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-21T00:00:00.000Z</StatusDate><Source id="1488193" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1004416">Lantheus Medical Imaging Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-29T00:00:00.000Z</StatusDate><Source id="1019073" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1004416">Lantheus Medical Imaging Inc</OwnerCompany><Country id="US">US</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>Diagnostic for the management of neuroendocrine tumors</AwardedIndication><DesignationType id="3">Diagnosis</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-04T00:00:00.000Z</MileStoneDate><Source id="2168101" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03344"><Name>Noradrenaline transporter</Name><SwissprotNumbers><Swissprot>O55192</Swissprot><Swissprot>P23975</Swissprot><Swissprot>P51143</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1cc(c(cc1CNC(=N)N)Br)OCCC[18F]</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1708137" number="WO-2011143360" title="Compositions, methods and systems for the synthesis and use of imaging agents"></PatentFamily><PatentFamily id="2491644" number="WO-2013036869" title="Compositions, methods, and systems for the synthesis and use of imaging agents"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lantheus Medical Imaging Inc" id="1004416"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>